Latest Global Markets News

Noxopharm says the FDA has supported its proposed Phase II design and chemical manufacturing strategy for SOF-SKN, its topical treatment candidate for cutaneous lupus erythematosus. The feedback improves regulatory clarity, but the trial remains targeted for the first half of calendar 2028 and is subject to further studies and regulatory requirements.

Kalamazoo Resources has secured A$10 million from a Saudi-led strategic investor and existing shareholder YT International at a 29% premium to its last close. The funding gives the Ashburton Gold Project more room to advance drilling, feasibility work and the Xanadu prospect evaluation.

Macquarie Global Small Companies Fund reported a A$561,000 operating profit in its first financial period after launching three unit classes in June. The fund ended the period with A$11.757 million in net assets, although its short start-up period offers little basis for judging full-year performance.

Marlin Global’s portfolio fell 6.3% before fees and tax in FY26 while its benchmark gained 30.5%, producing a NZ$17.3 million net loss. The Fisher Funds-managed vehicle is responding with broader sector coverage, faster portfolio turnover and an expanded research team.

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

Cleo Diagnostics has begun developing a multi-biomarker blood test for ovarian cancer screening in asymptomatic women, targeting a stated $150 billion global market. The prototype program will run alongside the company’s pre-surgical test, with initial proof-of-concept data expected early next quarter.

Zimi has secured an exclusive three-year distribution agreement with Directed for retail, direct-to-consumer and direct-to-business sales across Australia and New Zealand. The deal gives its next-generation Matter devices access to more than 10,000 retail outlets, although commercial terms and guaranteed sales volumes remain undisclosed.

Antipodes Global SMID Fund delivered a sharp improvement in FY2026, with profit attributable to unitholders rising to $22.73 million and net assets expanding more than eightfold to $183.65 million. The fund also added a new unit class and brought its P Class units to the ASX under ticker MIDS.

JPMorgan Global Research Enhanced Index Equity Trust (ASX:JRH) reported a sharp rise in FY2026 operating profit, driven primarily by investment revaluation gains as net assets expanded to almost A$2 billion. Distributions also surged, although the result remains exposed to global equity markets, foreign exchange and derivatives.

Kapstream Investment Trust will begin a 12-month on-market buy-back of its fully paid ordinary units, but has not disclosed a target quantity or dollar commitment. The responsible entity can pause or end the programme without notice.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.